Dear Editor

Caspase-2 is the most conserved member of the caspase family, but its physiological function(s) remains a matter of some debate \[[@CR1]\]. Recent work suggests that caspase-2 deficiency in mice makes animals more susceptible to tumorigenesis in various models leading to the concept that caspase-2 is a tumor suppressor \[[@CR1]--[@CR3]\]. One of the key characteristics of caspase-2 knockout (KO) MEFs in culture and cells from caspase-2-deficient tumors is a high degree of chromosomal instability (CIN), suggesting that caspase-2 prevents accumulation of aneuploid cells and CIN \[[@CR1]--[@CR4]\]. Real time imaging of KO cells following prolonged spindle-assembly checkpoint arrest suggests that caspase-2 is required for the deletion of cells carrying mitotic aberrations and this requires the catalytic function of caspase-2 \[[@CR5]\]. Another model that may explain increased CIN is suggested by Fava et al. \[[@CR6]\]. Their data suggest that supernumerary centrosomes trigger PIDDosome (a caspase-2 activating platform containing Pidd and Raidd)-dependent caspase-2 activation, which then cleaves MDM2, resulting in p53 stabilization and p21-dependent cell cycle arrest \[[@CR6]\]. Thus PIDDosome-mediated caspase-2 activation is predicted to be required to restrain polyploidization, preventing CIN, and therefore cancer. The main caveat with such a model is that, unlike *Casp2* KO animals, *Pidd* and *Raidd* KO mice are not susceptible to enhanced tumourigenesis indicating that PIDDosome is not responsible for the tumor suppressor function of caspase-2 \[[@CR7], [@CR8]\].

Most of the studies by Fava et al. used A549 lung adenocarcinoma cells, likely because it is a good in vitro model for cell cycle studies. To examine this pathway in other cell types, we generated *CASP2* KO U2OS (human osteosarcoma with wild-type p53) cells and compared them with A549 cells following treatment with the Aurora kinase B (AURKB) inhibitors, ZM447439 (as used by Fava et al.) or AZD1152-HQPA, to induce cytokinesis failure (Suppl. Fig. [S1a](#MOESM2){ref-type="media"}). AZD1152-HQPA is \>3000 times more specific toward AURKB compared with AURKA, while ZM447439 used by Fava et al. in most of their studies has lower selectivity \[[@CR9]\]. The results confirm some of the observations reported by Fava et al., including MDM2 cleavage and increased levels of p53 and p21 in parental cells treated with the inhibitors (Fig. [1a](#Fig1){ref-type="fig"}). We did not observe any difference between the two AURKB inhibitors. Fava et al. \[[@CR6]\] found that *CASP2* KO in A549 cells results in complete abrogation of MDM2 cleavage, p53 accumulation, and cell cycle arrest of tetraploid cells following cytokinesis failure. Our data are also consistent with these findings in *CASP2* KO A549 cells (Fig. [1a](#Fig1){ref-type="fig"}). However, we observed that *CASP2* KO U2OS cells, still showed increased p53 levels that appear to be independent of MDM2 cleavage in response to the AURKB inhibitors (Fig. [1a](#Fig1){ref-type="fig"}). The p53 response was not as robust as in the parental U2OS cells, as indicated by reduced p21 levels in the absence of caspase-2, and this has previously been documented \[[@CR1], [@CR2]\]. Interestingly, we also observed that MDM2 cleavage increases at 24 h and then decreases at 48 h following treatment in the non-synchronized A549, but not in U2OS cells (Suppl. Fig. [S1b](#MOESM2){ref-type="media"}), which is consistent with previous data \[[@CR6]\]. The data here, suggest different responses to AURKB inhibition in different cell types. From a functional perspective, DNA content analysis of *CASP2*KO U2OS cells treated with AZD1152-HQPA showed increased accumulation of polyploid (\>4N) cells when compared to parental U2OS cells. However, these results are not as dramatic as reported for A549 cells. In particular, only marginal differences were observed at 24 h following treatment with AZD1152-HQPA (Fig. [1b](#Fig1){ref-type="fig"}). We found that U2OS cells are efficiently blocked in cytokinesis by AZD1152-HQPA, ruling out any possibility that the observations are affected by asynchronous cell populations (Suppl. Fig. [S1c](#MOESM2){ref-type="media"}). Our data indicate that cytokinesis failure can trigger p53-mediated cell cycle arrest in the absence of caspase-2. This suggests the presence of alternative pathways and cell-type specific differences may drive caspase-2 responses to prevent polyploidization.Fig. 1Aurora kinase B inhibition results in p53 accumulation in both parental and *CASP2* KO U2OS cells. U2OS and A459 cells were synchronized in G1/S by treatment with 2 mM thymidine for 24 h. After 3 h release, the cells were treated with DMSO or AURKB inhibitors (400 nM AZD1152-HQPA (AZD) or 2 µM ZM447439 (ZM)) for 0, 24, and 48 h, followed by immunoblot and fluorescence-activated cell sorting (FACS) analyses. **a** Representative immunoblots of cell lysates from treated parental and *CASP2* KO cells. Antibodies used for immunoblotting are as indicated. **b** Percentage of U2OS parental and *CASP2* KO cells with polyploid (\>4N) DNA content following AZD treatment. Async, asynchronous

As AURKB has various functions in mitosis including mitotic condensation, spindle-assembly checkpoint and cytokinesis \[[@CR10]\], inhibiting AURKB by drugs such as AZD1152-HQPA can cause not only cytokinesis failure but also prolonged mitosis \[[@CR11]\] and DNA damage, that can induce a p53 response and lead to cell cycle arrest. This, in turn may also contribute to differential responses to these drugs in different cell types \[[@CR12]\].

In conclusion, we found that MDM2 cleavage in response to cytokinesis failure is not essential for cell cycle arrest and p53 accumulation in all cell types. Importantly, p53-mediated cell cycle arrest can still occur in the complete absence of caspase-2.
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